Trans-oral Robotic Surgery: Improved treatment option for throat cancer

Looks like a ray of hope can be seen for the patients suffering from early stage oropharyngeal carcinoma (cancer of the mouth, neck and throat), in form of robotic surgery.
Fortis Memorial Research Institute (FMRI) piloted a first of its kind study on the oropharyngeal cancer patients
Transoral robotic surgery (TORS) was conducted on 57 patients, under the leadership of Dr Surender Dabas, director, head, neck and thorax surgical oncology, FMRI. This surgical technique is instrumental in healing patients suffering from HPV negative cancers, which are caused mostly due to tobacco consumption.
A study, published in 'Oral Oncology' journal, was conducted between March 2013 to October 2015 on 57 patients suffering from early stage (I&II) oropharyngeal carcinoma, who underwent TORS robotic surgery.
Out of these 57 patients, 48 were males and nine were females, who underwent TORS. When presented, the mean age of the 57 patients was 59.4 years. The most common site of involvement was the base of tongue (BOT) in 31 (54.8 percent) patients. Twenty-four (42.1 percent) patients were stage I and 33 (57.9 percent) were Stage II at presentation. Forty-three (89.6 percent) patients were disease free with an overall survival of 93.8 percent at a mean follow-up of 29 months.
In TORS, the arms of the robot are strategically placed inside the mouth of the patient. The main advantage of TORS is, it allows the surgeon access, via the mouth, those areas that his/her hands probably couldn't reach.
TORS is a relatively new approach to remove cancers from areas in the throat that are difficult to access, including the base of tongue and low down in the bottom of the tonsil. These two areas, along with other parts of the oropharynx (soft palate, posterior oropharynx wall), remain the main tumour sites for which TORS is used.
Speaking at the conference, a cancer survivor, 76-year-old Amalkanti Bhowmik explained how opting for Robotic surgery proved a boon for him.
"I developed difficulty in swallowing food and soon even water in March this year. When my family took me to a doctor, an endoscopy revealed a lesion inside my throat. Subsequently, samples were sent for biopsy which confirmed stage I cancer of the Larynx (voice box). We went to several doctors thereafter to and most gave us the option of radiation followed by surgery, due to my age. However, we knew that the outcome of radiation would have led to further deterioration in my health. It was then that a nephew practicing medicine in UK recommended robotic surgery for my cancer. I have been disease free since my surgery and have been recovering well for my age," he said
Dr Dabas said, "In comparison to HPV negative cancers HPV positive cancers are more responsive to chemotherapy and radiation treatment. In India majority (nearly 70 percent) of all oropharyngeal cancers are HPV negative. This is the reason that TORS is a viable treatment option of HPV negative cancers. In order to avoid the side effects of undergoing a traditional open surgery, if the cancer has been caught at an early stage, TORS is adopted. Posing significant benefits to the patients, it prevents functional impairments to speech and swallowing. It is a fast surgery and precise, intricate and intensive in its execution. The amount of blood loss and the recovery time required post the operation is remarkably minimal. As this method can be implemented without prior chemo therapy, it allows the patient to be free of any toxicity associated with the same."
Dr Simardeep Singh Gill, zonal director, FMRI said, "This is a first-of-its-kind single institutional prospective study which evaluated the functional outcome and oncological outcome in early stage HPV negative carcinoma. This has been made possible by Dr Surender Dabas, who is one of the few surgeons who has conducted close to 500 robot-aided surgeries for head and neck cancer in India. This kind of surgery has a definite success rate in comparison to other forms of treatment for cancers of neck, throat and head"
Source:http://health.economictimes.indiatimes.com/news/diagnostics/trans-oral-robotic-surgery-improved-treatment-option-for-throat-cancer/58854130

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more